Google’s VC arm backs Oxford start-up according to : Insider Media Ltd

South East Muhammad AldalouThe venture capital arm of Google has participated in a multimillion-pound investment round in an Oxford University start-up behind a 'biological superglue' used to create effective vaccines. SpyBiotech's IP is based on research done by Oxford University's department of biochemistry and the Jenner Institute to separate the bacteria that gives people strep throat. SpyBiotech has secured £4m from GV, formerly Google Ventures, and Oxford Sciences Innovation, the university's own venture fund. In a statement, Sumi Biswas, associate professor at the Jenner Institute, said the superglue technology is viewed as "a game changer to enable faster development of effective vaccines against major global diseases". This urge to reconnect creates the "biotech superglue" that can be used to bond things together.




Back in January, Alphabet's health-focused technology arm Verily Life Sciences ("Verily") announced that it had received an $800 million investment from Singapore-based investment firm Temasek. SpyBiotech, a life sciences spinout from the U.K.'s Oxford University, has raised £4 million ($5 million) in seed funding from Oxford Sciences Innovation (OSI) and Alphabet investment arm GV (formerly Google Ventures). As traditional approaches to developing vaccines are typically time-consuming, and not always effective, SpyBiotech is working on what it calls a "proprietary protein superglue" technology. "We view this superglue technology as a game changer to enable faster development of effective vaccines against major global diseases. "SpyBiotech has established a novel approach using platform VLP vaccine technology that shows promise in a number of addressable markets," noted GV partner Tom Hulme.

Google's venture capital arm invests in Oxford biotech startup SpyBiotech

LONDON — Google 's venture capital arm has taken part in a £4 million investment round in a startup spun out of Oxford University that is trying to use "biotech superglue" to create new vaccines. This urge to reconnect creates the "biotech superglue" that can be used to bond things together. SpyBiotech is one of many biotech investments made by GV, the venture capital division of Google's parent company Alphabet. SpyBiotech is hoping it can use this principle to develop vaccines, rather than virus-causing bacteria, that will bind onto viral infections. GV, formerly Google Ventures, is backing SpyBiotech, a startup that is trying to commercialise a biological discovery that it believes can be used to create highly effective vaccines.


collected by :Lucy William

To follow all the new news about Health care